NEUROFIBROMATOSIS TYPE-1 - PATHOLOGY, CLINICAL-FEATURES AND MOLECULAR-GENETICS

被引:0
|
作者
VONDEIMLING, A
KRONE, W
MENON, AG
机构
[1] UNIV CINCINNATI, MED CTR, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA
[2] UNIV BONN, MED CTR, DEPT NEUROPATHOL, D-53105 BONN, GERMANY
[3] UNIV ULM, DEPT HUMAN GENET, D-89070 ULM, GERMANY
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neurofibromatosis type 1 (NF1) or von Recklinghausen neurofibomatosis, is a common heritable neurocutaneous disorder. This disorder appears to affect all races, with a prevalance estimated to be 1 in 3000. Approximately half of all cases of NF1 represent new mutations. The characteristics of NF1, which include cafe-au-lait spots, neurofibromas, Lisch nodules, optic glioma, osseous lesions, macrocephaly, short stature and mental retardation suggest that the genetic lesion affects the proper development of multiple organ systems. Within the past few years, the gene causing NF1 has been identified and the protein encoded by this gene, neurofibromin, has been the subject of detailed investigation. The NF1 gene spans over 350 kb of genomic DNA and encodes a protein product of 2818 amino acids. Neurofibromin is expressed in many different tissues. It is now known that one role of neurofibromin is as a GTPase activating protein (GAP), very likely in the same pathway of signal transduction as ras. Absence of neurofibromin in mice homozygously mutant for the NF1 gene results in profound developmental abnormalities. In mice that are heterozygous for NF1, an accelerated onset of tumor formation is observed. Combined with studies of tumors from NF1 patients showing homozygous deletions in the NF1 gene, these data suggest a role for NF1 as a ''tumor suppressor''. Evidence suggesting other roles played by neurofibromin, in control of proliferation in some situations and differentiation in others, is gradually bringing the previously hazy picture of this genetic disorder into sharper focus.
引用
收藏
页码:153 / 162
页数:10
相关论文
共 50 条
  • [21] MOLECULAR ANALYSIS OF NEUROFIBROMATOSIS TYPE-1 MUTATION
    XU, W
    LIU, L
    QI, Y
    MARGARET, P
    XU, G
    MARGARET, W
    DONALD, B
    PONDER, B
    CYTOGENETICS AND CELL GENETICS, 1991, 58 (3-4): : 2012 - 2012
  • [22] THE CHORDOMA - PATHOLOGY AND CLINICAL-FEATURES
    STAMBOLIS, C
    ALLES, JU
    KRACHT, J
    MEDIZINISCHE WELT, 1983, 34 (42): : 1172 - 1175
  • [23] Clinical phenotype and genetics of neurofibromatosis type 1
    Kehrer-Sawatzki, H.
    Mautner, V-F.
    MEDIZINISCHE GENETIK, 2009, 21 (04): : 519 - 530
  • [24] ADRENOLEUKODYSTROPHY - MOLECULAR-GENETICS, PATHOLOGY, AND LORENZOS OIL
    MOSER, HW
    POWERS, JM
    SMITH, KD
    BRAIN PATHOLOGY, 1995, 5 (03) : 259 - 266
  • [25] neurofibromatosis type-1 independent variants in a neurofibromatosis type-1 family
    Metaxa, Rafaella
    Miltiadous, Andri
    Gerasimou, Petroula
    Petridou, Natasa
    Athanasiou, Emily
    Costeas, Paul
    Anastasiadou, Violetta
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 1221 - 1221
  • [26] MOLECULAR PATHOLOGY OF TYPE-1 DIABETES
    CAMPBELL, IL
    HARRISON, LC
    MOLECULAR BIOLOGY & MEDICINE, 1990, 7 (04) : 299 - 309
  • [28] Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1
    Romo, Carlos G.
    Piotrowski, Anna F.
    Campian, Jian L.
    Diarte, Jose
    Rodriguez, Fausto J.
    Bale, Tejus A.
    Dahiya, Sonika
    Gutmann, David H.
    Lucas, Calixto-Hope G.
    Prichett, Laura
    Mellinghoff, Ingo
    Blakeley, Jaishri O.
    NEURO-ONCOLOGY, 2023, 25 (08) : 1474 - 1486
  • [29] Neurofibromatosis type-1
    Vidaud, D
    Bahuau, M
    Laurendeau, I
    Vidaud, M
    EUROCANCER 98, 1998, : 97 - 99
  • [30] NEUROFIBROMATOSIS TYPE-1
    COHEN, PR
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (21): : 1549 - 1549